Foxo SPAC Presentation Deck

RESEARCH Collaborations Physicians' Health Study VITAL Study COSMOS Trial FOXO Study Industry Pilot Studies FOXO INVESTOR DECK 2022 Page 28 • Epigenetic and health status data on 11,340 physicians • 30 years follow-up • 2,000+ mortality events and other major diseases • Epigenetic and health status data in 800 men and women • Clinical trial on vitamin D3 and omega-3 fatty acids (fish oil) supplementation • Focus on cancer, heart disease, and stroke • Epigenetic and health status data in 1,200 men and women • Clinical trial on multivitamins and cocoa flavanol supplementation • Focus on cancer, heart disease, and stroke • Epigenetic data in blood and saliva of ~5,000 men and women • Nation-wide study collecting blood, urine, saliva, and medical records. • Focus on tobacco use, alcohol use, diabetes, obesity, hypertension, and dyslipidemia • Parallel underwriting study with traditional health data and epigenetic data • Focused on achieving same or better risk classification from epigenetic data • Provides data for companies to tailor epigenetic testing into their unique workflows SCIENTIFIC Advisory Board Peter Laird, PhD Hui Shen, PhD Bret Barnes, PhD* Murdoc Khaleghi, MD* Randal Olson, PhD *FOXO Board of Directors Epigenetics Van Andel Institute (VAI) Bioinformatics Van Andel Institute (VAI) Biotechnology Illumina, Inc. Consumer Health WellnessFX AI Data scientist & Al researcher

View entire presentation